Screener
OS Therapies OSTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by OS Therapies in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: OS Therapies’s 10-Q, filed May 18, 2026.
- Filed
- May 18, 2026, 6:02 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-058070
| Line item | For the Three Months Ended / March 31, 2026 | For the Three Months Ended / March 31, 2025 |
|---|---|---|
| Interest expense | (75,344) | - |
| Non-operating expenses | (153,594) | - |
| Change in fair value of warrant liability | - | 1,122,561 |
| TOTAL OTHER (EXPENSE) INCOME | (228,893) | 1,122,627 |
| NET LOSS | (10,396,831) | (3,876,859) |
| NET LOSS available to common shareholders | $(10,396,831) | $(3,876,859) |
| Weighted-average # of shares | 38,674,663 | 21,249,423 |
| Basic and diluted loss per common share outstanding | $(0.27) | $(0.18) |
Item 1. Consolidated Financial Statements.
FAQ
- What is OS Therapies's EPS (diluted)?
- OS Therapies (OSTX) reported EPS (diluted) of -$0.27 in Q1 2026.
- How has OS Therapies's EPS (diluted) changed year-over-year?
- OS Therapies's EPS (diluted) decreased by 50.0% year-over-year, from -$0.18 to -$0.27.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about OS Therapies's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude